In the fifth instalment of our Medical Monitoring Masterclass to celebrate Clinical Trials Day 2026, we’re focussing on medical monitoring in generics development.

The Generics Landscape

Generic medicines are the backbone of accessible healthcare. They account for the majority of prescriptions dispensed globally, and their development represents a significant commercial and scientific endeavour. Yet the perception persists in some quarters that generics development is simpler than innovator drug development and therefore requires less rigorous clinical oversight.

In this blog, we challenge that perception. Even where clinical programmes for generics are smaller in scale than those for new chemical entities, the need for expert medical monitoring remains, and the consequences of inadequate oversight can be just as significant.

Typical Clinical Programmes for Generics

For most small-molecule generics, the regulatory pathway focuses on demonstrating bioequivalence rather than full clinical efficacy. This typically involves bioequivalence studies in healthy volunteers, comparative pharmacokinetic assessments, and, for certain categories, additional clinical or safety studies.

These programmes are much shorter and smaller than pivotal trials for new medicines. However, they still involve human participants, they still generate safety data that will be submitted to regulators, and they still require the kind of expert medical oversight that ensures that data are reliable, complete, and credible.

Healthy Volunteers: A Specific Responsibility

One aspect of generics clinical programmes that is sometimes underappreciated is the ethical and regulatory significance of studies conducted in healthy volunteers. These individuals have no prospect of therapeutic benefit from their participation – they are contributing to a programme purely in the interests of science and public health. That creates a particular responsibility on the part of the sponsor to ensure their safety is managed with the highest degree of care.

An experienced medical monitor brings clinical judgement to the review of healthy volunteer data that automated data review cannot replicate. The ability to contextualise an unexpected finding in order to distinguish a clinically significant signal from background noise, is a distinctly human skill, and one that Pharmora’s team exercises on every programme we support.

Data Integrity and Regulatory Credibility

For generics developers preparing for regulatory submission, whether to the FDA, MHRA, EMA, or other agencies, the integrity of the clinical dataset is paramount. Regulators will scrutinise adverse event reporting, protocol compliance, and the completeness of safety data, in addition to data supporting equivalence. Any weakness in these areas can trigger additional questions, delay a submission, or, in some cases, result in rejection.

The ICH E6(R3) quality by design principles, now coming into force across the world, apply to generics programmes just as they do to any other clinical development activity. Sponsors who engage medical monitoring expertise early, building quality into their programmes from the outset, will find that the regulatory review process is smoother, faster, and less expensive than those who do not.

Pharmora’s Approach to Generics Medical Monitoring

At Pharmora, we work with generics developers to provide medical monitoring that is scaled appropriately to the size and complexity of their programmes, without compromising quality or expertise. We understand that margins in the generics market are often tight, and we offer flexible, efficient services that deliver real value without unnecessary overhead.

Whether you are running a single bioequivalence study or a multi-study programme across multiple geographies, Pharmora has the expertise and the track record to provide the clinical oversight your programme requires. Our commitment is simple: quality without compromise, at every stage of development.

This blog is the final instalment in our series on the importance and value of medical monitoring. We hope it has been informative and thought-provoking. If any of the themes we have discussed resonate with the challenges you are facing in your clinical programme, we would be delighted to hear from you.

In case you missed a previous instalment, or are looking to read the rest of this exciting masterclass, click the links below to navigate through the series:
1 – What is it and why does it matter?
2 – Medical Monitoring for Biotechs
3 – Medical Monitoring and the Investor Perspective
4 – Medical Monitoring in Biosimilar Development

To find out how Pharmora can support your programme, contact us at info@pharmora.com or visit www.pharmora.com.